​

AgomAb Therapeutics Ownership | Who Owns AgomAb Therapeutics?

OverviewChart

AgomAb Therapeutics Ownership Summary

AgomAb Therapeutics is owned by 53.26% institutional investors, 5.90% insiders, and 40.85% retail investors. D. e. shaw is the largest institutional shareholder, holding 0% of AGMB shares. Federated Hermes Kaufmann Growth is the top mutual fund, with 1.99% of its assets in AgomAb Therapeutics shares.

AGMB Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockAgomAb Therapeutics53.26%5.90%40.85%
SectorHealthcare Stocks 245.53%12.09%-157.62%
IndustryBiotech Stocks 381.70%11.71%-293.40%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
D. e. shaw---
Jane street group---
Millennium management---
Lmr partners llp---
Laurion capital management lp---
Alyeska investment group---
Citadel advisors---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
D. e. shaw---
Jane street group---
Millennium management---
Lmr partners llp---
Laurion capital management lp---
Alyeska investment group---
Citadel advisors---

Top Buyers

HolderShares% AssetsChange
Jane street group---12.79K
D. e. shaw---15.33K
Citadel advisors---35.00K
Laurion capital management lp---50.00K
Alyeska investment group---75.00K

Top Sellers

HolderShares% AssetsChange
Lmr partners llp---300.00K
Millennium management---95.23K
Alyeska investment group---75.00K
Laurion capital management lp---50.00K
Citadel advisors---35.00K

Sold Out

HolderChange
Jane street group-12.79K
D. e. shaw-15.33K
Citadel advisors-35.00K
Laurion capital management lp-50.00K
Alyeska investment group-75.00K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026346.25%25,955,48211.14%532.32%13-59.38%6-
Mar 31, 202632-23,354,227-64-32---

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Federated Hermes Kaufmann Growth981.18K1.99%-
Federated Hermes Kaufmann R981.18K1.99%-
Fidelity Growth Compy Commingled Pl S671.14K1.36%-
Federated Hermes Kaufmann Small Cap Grow615.71K1.25%-
Federated Hermes Kaufmann Small Cap A615.71K1.25%-
Fidelity Growth Company Fund507.25K1.03%-
abrdn Healthcare Investors463.27K0.94%99.78K
abrdn World Healthcare414.46K0.84%101.73K
abrdn Life Sciences Investors329.62K0.67%75.91K
Fidelity Growth Company K6141.98K0.29%-

Recent Insider Transactions

DateNameRoleActivityValue
Oct 08, 2026Epstein David R-Buy$44.50K
Oct 05, 2026Epstein David R-Buy$42.85K
Oct 06, 2026Epstein David R-Buy$43.50K
Oct 06, 2026Kemula Pierre Thadee Victor Chief Financial OfficerBuy$17.08K
Oct 06, 2026Kemula Pierre Thadee Victor Chief Financial OfficerBuy$42.85K

Insider Transactions Trends

DateBuySell
2026 Q47-

AGMB Ownership FAQ

Who Owns AgomAb Therapeutics?

AgomAb Therapeutics shareholders are primarily institutional investors at 53.26%, followed by 5.90% insiders and 40.84% retail investors. The average institutional ownership in AgomAb Therapeutics's industry, Biotech Stocks , is 381.70%, which AgomAb Therapeutics falls below.

Who owns the most shares of AgomAb Therapeutics?

AgomAb Therapeutics’s largest shareholders are D. e. shaw (0 shares, 0%), Jane street group (0 shares, 0%), and Millennium management (0 shares, 0%). Together, they hold 0% of AgomAb Therapeutics’s total shares outstanding.

Does Blackrock own AgomAb Therapeutics?

BlackRock is not among the top 10 institutional shareholders of AgomAb Therapeutics.

Who is AgomAb Therapeutics’s biggest shareholder by percentage of total assets invested?

D. e. shaw is AgomAb Therapeutics’s biggest shareholder by percentage of total assets invested, with 0% of its assets in 0 AgomAb Therapeutics shares, valued at 0$.

Who is the top mutual fund holder of AgomAb Therapeutics shares?

Federated Hermes Kaufmann Growth is the top mutual fund holder of AgomAb Therapeutics shares, with 1.99% of its total shares outstanding invested in 981.18K AgomAb Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools